ABSTRACT
Human cancers are heterogeneous with respect to their molecular and genomic properties. Therefore, a given therapy may beneˆt only a subset of treated patients. This is particularly relevant for the new generation of cancer therapies that target speciˆc molecular pathways. Recent developments in molecular medicine provide new tools for identifying biomarkers to select patients who beneˆt from a targeted agent.
